When a COVID-19 vaccine shortage emerged as a major problem facing countries around the world, Samsung Biologics stepped up to play the role of a troubleshooter by signing a production contract with U.S. biotech firm Moderna in May. Starting in the third quarter of this year, the Korean drug manufacturer produced hundreds of millions of COVID-19 vaccine doses through a fill-and-finish production process at its Songdo factory in Incheon, southwest of Seoul.
All rights are reserved by the media that published this article.
When a COVID-19 vaccine shortage emerged as a major problem facing countries around the world, Samsung Biologics stepped up to play the role of a troubleshooter by signing a production contract with U.S. biotech firm Moderna in May. Starting in the third quarter of this year, the Korean drug manufacturer produced hundreds of millions of COVID-19 vaccine doses through a fill-and-finish production process at its Songdo factory in Incheon, southwest of Seoul.
All rights are reserved by the media that published this article.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article